#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pancreatic neuroendocrine tumour Autoimmune haemolytic anaemia Acute myeloid leukaemia refractory Haemophilia B with anti factor IX Thalassaemia Pulmonary alveolar haemorrhage Prodromal Alzheimer's disease Penile cancer Rett syndrome Philadelphia positive chronic myeloid leukaemia Neuroendocrine cell hyperplasia of infancy Cholangiosarcoma B-cell small lymphocytic lymphoma Insulinoma Deafness More trials…

    Learn about Rare Diseases

    Breast angiosarcoma metastatic – Diagnostics Acquired haemophilia – Trials in Disease Adrenocortical carcinoma – Trials in Disease Leiomyosarcoma metastatic – Basic Information Bronchopulmonary dysplasia – Basic Information Loeys-Dietz syndrome – Trials in Disease Mucopolysaccharidosis II Optic glioma – Diagnostics Glomerulonephritis membranous Cystic fibrosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Indacaterol Acetate Quizartinib Dihydrochloride Luspatercept Donanemab Octreotide Hydrochloride Ceftazidime Pentahydrate Nilutamide Aclidinium Bromide DCC-3084 Elamipretide Trihydrochloride Amg 193 Ketamine Zidesamtinib Ticagrelor SOVATELTIDE Ds-3939A PARECOXIB Istaroxime Kpl-404 Ambrosia Artemisiifolia (302) More therapies…

    Learn about Your Condition

    Autoimmune hepatitis Rheumatic disorder Vascular graft thrombosis Post procedural complication Infection Eyelid ptosis MELAS syndrome Epstein-Barr virus infection Migraine with aura Carcinoid tumour pulmonary Haemodynamic instability Cholangiocarcinoma COVID-19 Small for dates baby Endotracheal intubation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Cevostamab
    • Dexamethasone
    • Pomalidomide
    Germany

  • A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1
    Belgium Czechia France Germany Greece Italy +3

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Cevostamab
    • Elotuzumab
    • Carfilzomib
    Czechia Denmark France Germany Greece Italy +2

  • Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone Acetate
    Germany

  • AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    • Plasma cell myeloma
    Investigated Drugs:
    • AZD0120
    • Bortezomib
    • Carfilzomib
    France Germany Italy Norway Poland Spain

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Lenalidomide
    France Norway Spain
1 2 3 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!